MiR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1

FEBS Journal

Volumn 282, Issue 22, 2015, Pages 4376-4388

  Wang, Xinsheng ^a   Wu, Qiaoli ^b   Xu, Bin ^c   Wang, Pengfei ^c   Fan, Weijia ^b   Cai, Ying ^b   Gu, Xinquan ^a   Meng, Fanping ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

bladder cancer; matastasis; miR 124; proliferation; UHRF1

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN; UHRF1 PROTEIN, HUMAN;

ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; DNA METHYLATION; GENETICS; HUMAN; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VASCULARIZATION;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; URINARY BLADDER NEOPLASMS;

EID: 84954568459     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13502     Document Type: Article

References (33)

1. Hussain SA, &, James ND, (2003) The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 4, 489-497.
2. Besaratinia A, Cockburn M, &, Tommasi S, (2013) Alterations of DNA methylome in human bladder cancer. Epigenetics 8, 1013-1022.
3. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358, 1148-1159.
4. Bronner C, Krifa M, &, Mousli M, (2013) Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol 86, 1643-1649.
5. Mousli M, Hopfner R, Abbady AQ, Monte D, Jeanblanc M, Oudet P, Louis B, &, Bronner C, (2003) ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer 89, 120-127.
6. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, &, Hamamoto R, (2009) UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 101, 98-105.
7. Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, et al,. (2012) The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene 31, 4878-4887.
8. Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, et al,. (2014) UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196-209.
9. Ying L, Lin J, Qiu F, Cao M, Chen H, Liu Z, &, Huang Y, (2015) Epigenetic repression of regulator of G-protein signaling 2 by ubiquitin-like with PHD and ring-finger domain 1 promotes bladder cancer progression. FEBS J 282, 174-182.
10. Li XL, Xu JH, Nie JH, &, Fan SJ, (2012) Exogenous expression of UHRF1 promotes proliferation and metastasis of breast cancer cells. Oncol Rep 28, 375-383.
11. Yan F, Shao LJ, &, Hu XY, (2015) Knockdown of UHRF1 by lentivirus-mediated shRNA inhibits ovarian cancer cell growth. Asian Pac J Cancer Prev 16, 1343-1348.
12. Tien AL, Senbanerjee S, Kulkarni A, Mudbhary R, Goudreau B, Ganesan S, Sadler KC, &, Ukomadu C, (2011) UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis. Biochem J 435, 175-185.
13. Sato F, Tsuchiya S, Meltzer SJ, &, Shimizu K, (2011) MicroRNAs and epigenetics. FEBS J 278, 1598-1609.
14. Chu M, Chang Y, Guo Y, Wang N, Cui J, &, Gao WQ, (2015) Regulation and methylation of tumor suppressor MiR-124 by androgen receptor in prostate cancer cells. PLoS One 10, e0116197.
15. Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, &, Steenbergen RD, (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 9, 167.
16. Butz H, Szabo PM, Khella HW, Nofech-Mozes R, Patocs A, &, Yousef GM, (2015) miRNA-target network reveals miR-124 as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget 6, 12543-12557.
17. Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, Xu X, Wu J, Zhu Y, Zheng X, et al,. (2013) MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. J Transl Med 11, 276.
18. Zhang T, Wang J, Zhai X, Li H, Li C, &, Chang J, (2014) MiR-124 retards bladder cancer growth by directly targeting CDK4. Acta Biochim Biophys Sin (Shanghai) 46, 1072-1079.
19. Neo WH, Yap K, Lee SH, Looi LS, Khandelia P, Neo SX, Makeyev EV, &, Su IH, (2014) MicroRNA miR-124 controls the choice between neuronal and astrocyte differentiation by fine-tuning Ezh2 expression. J Biol Chem 289, 20788-20801.
20. Cheng LC, Pastrana E, Tavazoie M, &, Doetsch F, (2009) miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat Neurosci 12, 399-408.
21. Yoo AS, Staahl BT, Chen L, &, Crabtree GR, (2009) MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 460, 642-646.
22. Zhang S, Zhang D, &, Sun B, (2007) Vasculogenic mimicry: current status and future prospects. Cancer Lett 254, 157-164.
23. Wu G, Wang Y, Lu X, He H, Liu H, Meng X, Xia S, Zheng K, &, Liu B, (2015) Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer 15, 182.
24. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, &, Hermeking H, (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591-2600.
25. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, &, Liu L, (2014) Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33, 514-524.
26. Wan HY, Li QQ, Zhang Y, Tian W, Li YN, Liu M, Li X, &, Tang H, (2014) MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett 355, 148-158.
27. Shi Z, Chen Q, Li C, Wang L, Qian X, Jiang C, Liu X, Wang X, Li H, Kang C, et al,. (2014) MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro Oncol 16, 1341-1353.
28. Unoki M, (2011) Current and potential anticancer drugs targeting members of the UHRF1 complex including epigenetic modifiers. Recent Pat Anticancer Drug Discov 6, 116-130.
29. Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J, Franci C, Huang B, Huang J, Yam GC, et al,. (2005) Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16, 5621-5629.
30. Zhang Y, Huang Z, Zhu Z, Zheng X, Liu J, Han Z, Ma X, &, Zhang Y, (2014) Upregulated UHRF1 promotes bladder cancer cell invasion by epigenetic silencing of KiSS1. PLoS One 9, e104252.
31. Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli M, et al,. (2012) UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene 31, 5061-5072.
32. Achour M, Jacq X, Ronde P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, et al,. (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27, 2187-2197.
33. Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, &, Bronner C, (2011) Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 30, 41.